New drug combo takes on deadly brain tumor

NCT ID NCT04656535

Ongoing Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a combination of two drugs (domvanalimab and zimberelimab) that aim to help the immune system fight glioblastoma, an aggressive brain cancer that has returned after initial treatment. About 46 participants will receive the drugs to check safety and see how the drugs affect the tumor and immune cells. The study is not yet testing whether the treatment improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Domvanalimab and zimberelimab (two immune-boosting drugs given together)
What this could lead to: If it works, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong: This is a very early (phase 0/I) and small trial (46 people) focused on safety, not yet testing if the drugs actually shrink tumors or extend life. The combination may cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
University of California San Francisco

San Francisco, California, 94143, United States
Yale University

New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.